104 related articles for article (PubMed ID: 8222190)
1. Nafamostat mesilate reduces blood loss during open heart surgery.
Murase M; Usui A; Tomita Y; Maeda M; Koyama T; Abe T
Circulation; 1993 Nov; 88(5 Pt 2):II432-6. PubMed ID: 8222190
[TBL] [Abstract][Full Text] [Related]
2. Effects of nafamostat mesilate on platelets and coagulofibrinolysis during cardiopulmonary bypass surgery.
Tanaka K; Kondo C; Takagi K; Sato T; Yada I; Yuasa H; Kusagawa M
ASAIO J; 1993; 39(3):M545-9. PubMed ID: 8268595
[TBL] [Abstract][Full Text] [Related]
3. Nafamostat mesilate reduces blood-foreign surface reactions similar to biocompatible materials.
Usui A; Hiroura M; Kawamura M; Hibi M; Yoshida K; Murakami F; Tomita Y; Ooshima H; Murase M
Ann Thorac Surg; 1996 Nov; 62(5):1404-11. PubMed ID: 8893576
[TBL] [Abstract][Full Text] [Related]
4. Effects of nafamostat mesilate and minimal-dose aprotinin on blood-foreign surface interactions in cardiopulmonary bypass.
Kaminishi Y; Hiramatsu Y; Watanabe Y; Yoshimura Y; Sakakibara Y
Ann Thorac Surg; 2004 Feb; 77(2):644-50. PubMed ID: 14759453
[TBL] [Abstract][Full Text] [Related]
5. [Experimental study on heparin-free cardiopulmonary bypass using nafamostat mesilate (FUT-175) and heparin-coated circuit].
Takano H; Miyamoto Y; Kaneko M; Matsuwaka R; Kuratani T; Amemiya A; Nakano S; Matsuda H
Nihon Kyobu Geka Gakkai Zasshi; 1993 Nov; 41(11):2166-73. PubMed ID: 8283086
[TBL] [Abstract][Full Text] [Related]
6. Nafamostat mesilate administration during cardiopulmonary bypass decreases postoperative bleeding after cardiac surgery.
Sato T; Tanaka K; Kondo C; Morimoto T; Yada I; Yuasa H; Kusagawa M; Deguchi K
ASAIO Trans; 1991; 37(3):M194-5. PubMed ID: 1751106
[TBL] [Abstract][Full Text] [Related]
7. Coagulation and fibrinolysis system in aortic surgery under deep hypothermic circulatory arrest with aprotinin: the importance of adequate heparinization.
Okita Y; Takamoto S; Ando M; Morota T; Yamaki F; Matsukawa R; Kawashima Y
Circulation; 1997 Nov; 96(9 Suppl):II-376-81. PubMed ID: 9386127
[TBL] [Abstract][Full Text] [Related]
8. Effects of cell saver autologous blood transfusion on blood loss and homologous blood transfusion requirements in patients undergoing cardiac surgery on- versus off-cardiopulmonary bypass: a randomised trial.
Niranjan G; Asimakopoulos G; Karagounis A; Cockerill G; Thompson M; Chandrasekaran V
Eur J Cardiothorac Surg; 2006 Aug; 30(2):271-7. PubMed ID: 16829083
[TBL] [Abstract][Full Text] [Related]
9. Tranexamic acid and aprotinin in primary cardiac operations: an analysis of 220 cardiac surgical patients treated with tranexamic acid or aprotinin.
Dietrich W; Spannagl M; Boehm J; Hauner K; Braun S; Schuster T; Busley R
Anesth Analg; 2008 Nov; 107(5):1469-78. PubMed ID: 18931201
[TBL] [Abstract][Full Text] [Related]
10. Heparin-coated versus uncoated extracorporeal circuit in patients undergoing coronary artery bypass graft surgery.
Oliver WC; Nuttall GA; Ereth MH; Santrach PJ; Buda DA; Schaff HV
J Cardiothorac Vasc Anesth; 2003 Apr; 17(2):165-70. PubMed ID: 12698396
[TBL] [Abstract][Full Text] [Related]
11. Clinical evaluation of a new synthetic protease inhibitor in open heart surgery. Effect on plasma serotonin and histamine release and blood conservation.
Miyamoto Y; Nakano S; Kaneko M; Takano H; Matsuda H
ASAIO J; 1992; 38(3):M395-8. PubMed ID: 1281015
[TBL] [Abstract][Full Text] [Related]
12. Infusion of autologous platelet rich plasma does not reduce blood loss and product use after coronary artery bypass. A prospective, randomized, blinded study.
Tobe CE; Vocelka C; Sepulvada R; Gillis B; Nessly M; Verrier ED; Hofer BO
J Thorac Cardiovasc Surg; 1993 Jun; 105(6):1007-13; discussion 1013-4. PubMed ID: 8501929
[TBL] [Abstract][Full Text] [Related]
13. Perioperative use of tirofiban hydrochloride (Aggrastat) does not increase surgical bleeding after emergency or urgent coronary artery bypass grafting.
Bizzarri F; Scolletta S; Tucci E; Lucidi M; Davoli G; Toscano T; Neri E; Muzzi L; Frati G
J Thorac Cardiovasc Surg; 2001 Dec; 122(6):1181-5. PubMed ID: 11726894
[TBL] [Abstract][Full Text] [Related]
14. [Reduction of postoperative blood loss and donor blood use in heart surgery with aprotinin: experience with various dosages].
Carrel T; Bauer E; Garcia E; von Segesser L; Niederhäuser U; Schönbeck M; Laske A; Turina M
Helv Chir Acta; 1991 Sep; 58(3):365-78. PubMed ID: 1722785
[TBL] [Abstract][Full Text] [Related]
15. Investigation of a thrombin inhibitor peptide as an alternative to heparin in cardiopulmonary bypass surgery.
Chomiak PN; Walenga JM; Koza MJ; Reilly TM; Turlapathy P; Pifarre R
Circulation; 1993 Nov; 88(5 Pt 2):II407-12. PubMed ID: 7993389
[TBL] [Abstract][Full Text] [Related]
16. Perioperative monitoring of primary and secondary hemostasis in coronary artery bypass grafting.
Hertfelder HJ; Bös M; Weber D; Winkler K; Hanfland P; Preusse CJ
Semin Thromb Hemost; 2005; 31(4):426-40. PubMed ID: 16149021
[TBL] [Abstract][Full Text] [Related]
17. Prostacyclin infusion during extracorporeal circulation foe coronary bypass.
Rådegran K; Arén C; Teger-Nilsson AC
J Thorac Cardiovasc Surg; 1982 Feb; 83(2):205-11. PubMed ID: 7035754
[TBL] [Abstract][Full Text] [Related]
18. Aprotinin reduces bleeding and blood product use in patients treated with clopidogrel before coronary artery bypass grafting.
Lindvall G; Sartipy U; van der Linden J
Ann Thorac Surg; 2005 Sep; 80(3):922-7. PubMed ID: 16122456
[TBL] [Abstract][Full Text] [Related]
19. Nafamostat mesilate, as a treatment for heparin resistance, is not associated with perioperative ischemic stroke in patients undergoing cardiac surgery with cardiopulmonary bypass.
Kikura M; Tanaka K; Hiraiwa T; Tanaka K
J Cardiothorac Vasc Anesth; 2012 Apr; 26(2):239-44. PubMed ID: 22019206
[TBL] [Abstract][Full Text] [Related]
20. The influence of preoperative anticoagulation on heparin response during cardiopulmonary bypass.
Dietrich W; Spannagl M; Schramm W; Vogt W; Barankay A; Richter JA
J Thorac Cardiovasc Surg; 1991 Oct; 102(4):505-14. PubMed ID: 1833592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
